18 Dec 2012 07:00
To: Companies Announcement Office
FOR IMMEDIATE RELEASE
18 December 2012
BIOQUELL PLC
Appointment of a non-executive director
In accordance with the Listing Rules of the Financial Services Authority, Bioquell PLC ("Bioquell") is pleased to announce that Mr. Christopher Mills will join the Board as a Non-Executive Director with effect from 18 December 2012.
Mr. Mills is the Chief Executive and Investment Manager of North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"), a director of Oryx International Growth Fund Limited ("Oryx") and is the Chief Investment Officer, and a member, of Harwood Capital LLP. NASCIT and Oryx own approximately 22.1% of Bioquell's issued ordinary share capital.
Mr. Mills is also a director of Sunlink Health Systems Inc, Bionostics Holdings Limited, Hampton Investment Properties, Second London American Trust PLC (in members' voluntary liquidation), Glass America, Inc, Progeny, Inc, Global Options, Celsis International Limited and MJ Gleeson PLC.
Commenting on the appointment, Nigel Keen, Chairman of Bioquell PLC said:
"We welcome Christopher Mills to our Board. He has a long record of successful investing in technology companies - and he is also the Chief Executive Officer of investment funds which together are our largest shareholder. We look forward to his contribution to our Board."
Enquiries:
Nigel Keen Chairman
Nick Adams Chief Executive
Bioquell PLC
01264 835 900